Trial Profile
A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam, for Patients Suffering From Epilepsy and Coming From the Study N01175 (NCT00175903)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary) ; Carbamazepine; Valproic acid
- Indications Epilepsy; Seizures
- Focus Adverse reactions
- Acronyms KOMET
- Sponsors UCB
- 19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record
- 19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record
- 05 Dec 2008 Results were presented at the 2008 Annual Meeting of the American Epilepsy Society.